Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 3, 2004, Pages 1142-1151

  Wilhelm, Clare J ^a   Johnson, Robert A ^e   Lysko, Paul G ^c   Eshleman, Amy J ^a   Janowsky, Aaron ^a,b,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIHYDROTETRABENAZINE; DOPAMINE TRANSPORTER; LOBELINE; METHAMPHETAMINE; MONOAMINE DERIVATIVE; TYRAMINE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER;

ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; EFFUSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; STATISTICAL SIGNIFICANCE; TEMPERATURE DEPENDENCE;

BIOLOGICAL TRANSPORT; CELLS, CULTURED; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; LOBELINE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHAMPHETAMINE; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NICOTINIC AGONISTS; TRANSFECTION; TRITIUM; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 4243050488     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.067314     Document Type: Article

References (36)

1. Brown JM, Hanson GR, and Fleckenstein AE (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74:2221-2223.
2. Cubells JF, Rayprt S, Rajendran G, and Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14:2260-7221.
3. Di Chiara G (2002) Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 137:75-114.
4. Dwoskin LP and Crooks PA (2002) A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 63:89-98.
5. Erickson JD, Eiden LE, and Hoffman BJ (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA 89:10993-10997.
6. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, and Janowsky A (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289:877-885.
7. Eshleman AJ, Henningsen RA, Neve KA, and Janowsky A (1994) Release of dopamine via the human transporter. Mol Pharmacol 45:312-316.
8. Eshleman AJ, Stewart E, Evenson AK, Mason JN, Blakely RD, Janowsky A, and Neve KA (1997) Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters. J Neurochem 69:1459-1466.
9. Eshleman AJ, Wolfrum K, Johnson RA, Galey KM, and Janowsky A (2002) Expression of the vesicular monoamine transporter protein in transfected HEK cells: membrane fractions. Abstract No. 343.12. Society for Neuroscience, Washington, DC.
10. Fleckenstein AE, Metzger RR, Gibb JW, and Hanson GR (1997) A rapid and reversible change in dopamine transporters induced by methamphetamine. Eur J Pharmacol 323:R9-R10.
11. Grace AA (2000) The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95:S119-S128.
12. Gulley JM, Doolen S, and Zahniser NR (2002) Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J Neurochem 83:400-411.
13. Johnson RA, Eshleman AJ, Meyers T, Neve KA, and Janowsky A (1998) [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse 30:97-106.
14. Jones SR, Gainetdinov RR, Wightman RW, and Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979-1986.
15. Jones SR, Joseph JD, Barak LS, Caron MG, and Wightman RM (1999) Dopamine neuronal transport kinetics and effects of amphetamine. J Neurochem 73:2406-2414.
16. Liu Y and Edwards RH (1997) Differential localization of vesicular acetylcholine and monoamine transporters in PC12 cells, but not CHO cells. J Cell Biol 139:907-916.
17. Lysko PG, Weinstock J, Webb CL, Brawner ME, and Elshourbagy NA (1999) Identification of a small-molecule, nonpeptide macrophage scavenger receptor antagonist. J Pharmacol Exp Ther 289:1277-1285.
18. Merickel A, Rosandich P, Peter D, and Edwards RH (1995) Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J Biol Chem 270:25798-25804.
19. Miller DK, Crooks PA, Teng L, Witkin JM, Munzar P, Goldberg SR, Acri JB, and Dwoskin LP (2001) Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther 296:1023-1034.
20. Partilla JS, Dersch CM, Yu H, Rice KR, and Rothman RB (2000) Neurochemical neutralization of amphetamine-type stimulants in rat by the indatraline analog (-)-HY038. Brain Res Bull 53:821-826.
21. Pifl C, Drobny H, Reither H, Hornykiewicz O, and Singer EA (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol 47: 368-373.
22. Rao TS, Correa LD, Adams P, Santori EM, and Sacaan AI (2003) Pharmacological characterization of dopamine, norepinephrine and serotonin release in the rat prefrontal cortex by neuronal nicotinic acetylcholine receptor agonists. Brain Res 990:203-208.
23. Riddle EL, Topham MK, Haycock JW, Hanson GR, and Fleckenstein AE (2002) Differential trafficking of the vesicular monoamine transpoter-2 by methamphetamine and cocaine. Eur J Pharmacol 449:71-74.
24. Robbins AK and Horlick RA (1998) Macrophage scavenger receptor confers an adherent phenotype to cells in culture. Biotechniques 25:240-244.
25. Rothman RB, Partilla JS, Baumann MH, Dersch CM, Carroll FI, and Rice KC (2000) Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse 35:222-227.
26. Sabol KE and Seiden LS (1998) Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res 806:69-78.
27. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, and Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97:6850-6855.
28. Schmitz Y, Lee CJ, Schmauss C, Gonon F, and Sulzer D (2001) Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters and synaptic vesicle stores. J Neurosci 21:5916-5924.
29. Sheff DR, Daro EA, Hull M, and Mellman I (1999) The receptor recycling pathway contains two distinct populations of early endosomes with different sorting functions. J Cell Biol 145:123-139.
30. Sievert MK, Thiriot DS, Edwards RH, and Ruoho AE (1998) High-efficiency expression and characterization of the synaptic-vesicle monoamine transporter from baculovirus-infected insect cells. Biochem J 330:959-966.
31. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, and Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102-4108.
32. Teng L, Crooks PA, and Dwoskin LP (1998) Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J Neurochem 71:258-265.
33. Thiriot DS and Ruoho AE (2001) Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. J Biol Chem 276:27304-27315.
34. Ugarte YV, Rau KS, Riddle EL, Hanson GR, and Fleckenstein AE (2003) Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors. Eur J Pharmacol 472:165-171.
35. Vindis C, Seguelas MH, Bianchi P, Parini A, and Cambon C (2000) Monoamine oxidase B induces ERK-dependent cell mitogenesis by hydrogen peroxide generation. Biochem Biophys Res Commun 271:181-185.
36. Vizi ES (1998) Different temperature dependence of carrier-mediated (cytoplasmic) and stimulus-evoked (exocytotic) release of transmitter: a simple method to separate the two types of release. Neurochem Int 33:359-366.